European Medicines Agency (EMA) validates Type II variation marketing authorization application for avapritinib for treatment of advanced systemic mastocytosis (SM)

Validation of the application confirms that the submission is sufficiently complete to begin the formal review process for this selective inhibitor of D816V mutant KIT being developed to treat this rare disease that causes uncontrolled proliferation and activation of mast cells

Biospace Inc.